Non-small cell lung cancer+1
Not recruitingStudy of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy
Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy
- Disease:Non-small cell lung cancerNon-small cell lung cancer metastatic
- Substances:Anhydrous DocetaxelDostarlimab+1
Spain- Participants:18–64 years · 65+ years
- Substances:Anhydrous Docetaxel
- Sponsor:iOnctura SA










